Data reproducibility issues on evidence synthesis of adverse events associated with HER2-targeted antibody-drug conjugates.
作者信息
Wu Dan-Na, Guan Ai-Jia, Li Guo-Fu
机构信息
Department of Pharmacy, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, Hainan, China.
First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China.
出版信息
EClinicalMedicine. 2023 Mar 16;58:101904. doi: 10.1016/j.eclinm.2023.101904. eCollection 2023 Apr.
Abstract
摘要
相似文献
1
Data reproducibility issues on evidence synthesis of adverse events associated with HER2-targeted antibody-drug conjugates.与HER2靶向抗体药物偶联物相关的不良事件证据综合中的数据可重复性问题。
EClinicalMedicine. 2023 Mar 16;58:101904. doi: 10.1016/j.eclinm.2023.101904. eCollection 2023 Apr.
2
Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis.临床试验中与HER2靶向抗体药物偶联物相关的治疗相关不良事件：系统评价和荟萃分析
EClinicalMedicine. 2022 Dec 27;55:101795. doi: 10.1016/j.eclinm.2022.101795. eCollection 2023 Jan.
3
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.在 HER2 阳性乳腺癌中实施抗体药物偶联物 (ADC)：现状和未来方向。
Breast Cancer Res. 2021 Aug 11;23(1):84. doi: 10.1186/s13058-021-01459-y.
4
Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).MMAE-曲妥珠单抗抗体药物偶联物（ADC）的研发与生物学评估。
Breast Cancer. 2021 Jan;28(1):216-225. doi: 10.1007/s12282-020-01153-5. Epub 2020 Sep 5.
5
Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon.揭示抗体药物偶联物在治疗三阴性乳腺癌中的应用：治疗趋势与未来展望。
Med Oncol. 2022 Dec 2;40(1):25. doi: 10.1007/s12032-022-01884-9.
6
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.曲妥珠单抗药物偶联物治疗领域的不断发展：HER2 阳性乳腺癌以外的未来前景。
Cancer Treat Rev. 2023 Feb;113:102500. doi: 10.1016/j.ctrv.2022.102500. Epub 2022 Dec 24.
7
Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer.抗 HER2 单链抗体-DM1 偶联物治疗 HER2 阳性癌症的治疗潜力。
Signal Transduct Target Ther. 2017 May 19;2:17015. doi: 10.1038/sigtrans.2017.15. eCollection 2017.
8
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.人类临床试验中与抗体药物偶联物相关的眼部不良事件。
J Ocul Pharmacol Ther. 2015 Dec;31(10):589-604. doi: 10.1089/jop.2015.0064. Epub 2015 Nov 5.
9
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?抗体偶联药物在乳腺癌中的应用：除了 HER2 还有什么？
Cancer J. 2022;28(6):436-445. doi: 10.1097/PPO.0000000000000629.
10
In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.半胱氨酸及其定点偶联曲妥珠单抗抗体药物偶联物的体内外评价。
PLoS One. 2014 Jan 14;9(1):e83865. doi: 10.1371/journal.pone.0083865. eCollection 2014.
本文引用的文献
1
Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis.临床试验中与HER2靶向抗体药物偶联物相关的治疗相关不良事件：系统评价和荟萃分析
EClinicalMedicine. 2022 Dec 27;55:101795. doi: 10.1016/j.eclinm.2022.101795. eCollection 2023 Jan.
2
Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study.数据提取在不良事件证据综合实践中的有效性：再现性研究。
BMJ. 2022 May 10;377:e069155. doi: 10.1136/bmj-2021-069155.
3
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
4
Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.UJVIRA（ZRC-3256，曲妥珠单抗恩美坦辛）与 Kadcyla（曲妥珠单抗恩美坦辛）治疗人表皮生长因子受体 2 阳性转移性乳腺癌的疗效、安全性、药代动力学和免疫原性比较：印度一项随机、开放标签、多中心研究。
Clin Breast Cancer. 2022 Jun;22(4):300-307. doi: 10.1016/j.clbc.2021.11.006. Epub 2021 Nov 27.
5
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.曲妥珠单抗-美坦新偶联物与曲妥珠单抗联合紫杉醇用于 I 期 HER2 阳性乳腺癌（ATEMPT）的辅助治疗：一项随机临床试验。
J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2.
6
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.曲妥珠单抗-美坦新偶联物联合或不联合帕妥珠单抗对比曲妥珠单抗联合紫杉类药物用于人表皮生长因子受体 2 阳性晚期乳腺癌：来自 MARIANNE 的最终结果。
Cancer. 2019 Nov 15;125(22):3974-3984. doi: 10.1002/cncr.32392. Epub 2019 Jul 18.
7
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.曲妥珠单抗-美坦新偶联物对比医师选择的治疗方案用于治疗既往接受过治疗的人表皮生长因子受体 2（HER2）阳性转移性乳腺癌患者（TH3RESA）：一项随机、开放性、III 期临床试验的最终总生存结果。
Lancet Oncol. 2017 Jun;18(6):743-754. doi: 10.1016/S1470-2045(17)30313-3. Epub 2017 May 16.
8
Trastuzumab emtansine for HER2-positive advanced breast cancer.曲妥珠单抗-美坦新偶联物用于治疗人表皮生长因子受体 2 阳性的晚期乳腺癌。
N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1.
Zotero 插件